|
The following is a round-up of updates by London-listed companies, issued last Thursday and Friday, and not separately reported by Alliance News: ---------- PHSC PLC - Aylesford, Kent-based provider of health, safety, hygiene and environmental consultancy and security solutions - Estimates £1.3 million in revenue for the five months that ended August 31, broadly stable compared to the previous year. Cost of sales and general overheads were marginally higher on-year. However, the firm says it swung to a loss before interest, tax, depreciation and amortisation of £52,000 compared to an Ebitda profit of £8,000 a year earlier. PHSC attributes this to higher costs ‘for additional support with finance and operations and certain board changes’. The firm plans to update further in its interim results due mid November 2025. ---------- Igraine PLC - London-based investor in healthcare and life sciences - Posts a wider loss in the six months that ended June 30. Pretax loss widens to £125,752 from £67,402, as Igraine books a £34,819 loss on revaluation of investments, compared to a gain of £37,581 the previous year. The firm reports no revenue, unchanged on-year, but other operating income of £13,448, up from none reported. Administrative costs are marginally lower at £104,381 compared to £105,374 in 2024. The firm notes that its investee Fixit Medical Ltd completed a refinancing scheme during the first half through a director subscription priced at £1,150 per share, which revalues Igraine’s holding at £499,100, it said. ---------- Octopus Titan VCT PLC - London-based investor in early-stage companies - Posts a lower net asset value per share of 47.7 pence at June 30, versus 53.3p on-year, as total NAV falls to £786.5 million from £892.5 million. Still, the firm’s pretax loss narrows to £36.9 million in the first half from £116.2 million the previous year. Octopus Titan notes a £1.2 million gain on the disposal of fixed asset investments, compared to a loss of £572,000 a year earlier. Loss per share narrows to 0.1p from 2.1p. Still, Chair Tom Leader says: ‘The continued decline in NAV is disappointing and reflects a combination of factors, including portfolio company specific challenges alongside broader market volatility, macroeconomic headwinds, and the impact of foreign exchange movements.’ The company plans a short-term ‘transition period during which Octopus will focus its resources on improving performance of the existing portfolio, a continuation of the portfolio first strategy initiated in mid-2024, while the board will closely monitor performance.’ It adds that fund manager Octopus ‘has agreed to rebate up to 20% of the annual management fee during the transition period if it does not deliver target performance and realisations.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
